Pre-market · Oct 6, 4:10 am ET · After hours $4.76 -0.42%
Open$4.16
Prev close$4.12
Day range$4.06 – $4.94
Volume67.28M
Market cap$2.56B
P/E (TTM)–
Dividend yield–
RXRX Stock News
Headlines matching Recursion Pharmaceuticals or the RXRX ticker, most recent first.
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold RatingMarket news · 21 Sep 2026
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 21 Sep 2026
J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy RatingMarket news · 16 Sep 2026
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold RatingMarket news · 6 Aug 2026
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8Market news · 6 Aug 2026
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3Market news · 17 Aug 2026
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6Market news · 12 Aug 2026
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5Market news · 14 May 2026
J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10Market news · 30 Apr 2026
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6Market news · 26 Feb 2026
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $7Market news · 14 Jan 2026
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $8Market news · 6 Aug 2025
TR | OpenAI - 4o Initiates Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $6Market news · 6 Aug 2025
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $5Market news · 18 Jun 2025
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5Market news · 17 Jun 2025
Discussion
No comments yet — be the first to weigh in on RXRX.
No comments yet — be the first to weigh in on RXRX.